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Abstract
In this paper, support vector machine and condensed graph of reaction (CGR) approaches have been used to predict the
regioselectivity of aromatic hydroxylation for human CYP1A2 substrates. Experimental data on aromatic hydroxylation for
human cytochrome CYP1A2 (observed molecular or Breal^ transformations) used in the modeling were extracted from the
Metabolite database and the XenoSite database. In addition, all potential but unobserved (Bunreal^) transformations were
generated. The dataset containing Breal^ and Bunreal^ transformations was converted into an ensemble of CGRs representing
pseudomolecules with conventional (single, double, aromatic, etc.) bonds and dynamic bonds characterizing chemical transfor-
mations. ISIDA fragment descriptors generated for CGRs were used for the modeling. The models have been validated in three
times repeated fivefold cross-validation on the training set and then on an external set. The final model was constructed by
consensus over models built on different descriptors sets. Predictive performance of our model on the external test set was similar
to that of XenoSite and Way2Drug tools. Unlike previously used atom labeling-based approaches, the proposed CGR-based
representation of metabolic transformations could be applied to different types of reactions catalyzed by the same enzyme and
therefore, it is more suitable for automatized handling of metabolic data.
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1 Introduction
Computational assessment of adsorption, distribution, metabo-
lism, excretion, and toxicity (ADMET) properties [1] can signif-
icantly reduce costs of drug discovery process. Metabolic fate of
xenobiotics in the human organism is one of the most difficult
properties to predict. The point is that substrate oxidation could be
catalyzed successively by different enzymes (belongingmostly to
P450 cytochrome family). In phase Imetabolism stage,molecules
are oxidized and converted into their hydroxylated derivatives.
These oxidations are often followed by conjugation reactions at
phase IImetabolism stage. Due to these transformations, the com-
pounds become more polar (i.e., more soluble in water) which
facilitates their excretion. Metabolic transformations may also
modulate biological activities or toxicity of the ingested com-
pounds. Thus, in order to anticipate undesired side effects, it is
important to predict metabolites which could be formed.
Generally, computational studies [2, 3] reported so far focus
on two main problems: (i) assessments of the specificity of a
molecule toward different isoforms of cytochrome P450 and
(ii) prediction of the most likely metabolic labile site(s). Some
computational studies (docking, molecular interaction fields)
[4–8] require explicit information about enzyme structure,
whereas the others (QM calculations, QSAR, pharmacophore)
[9–15] use only substrate structure. Up to now, reported ligand-
based predictions outperform related structure-based ones.
Thus, Sheridan et al. [16] developed QSAR models combining
structural and physical property descriptors for predicting
CYP3A4, 2D6, and 2D9 regioselectivity. They demonstrated
that related QSAR models performed similarly to mechanism-
based MetaSite approach. Swamidass et al. [17–19] reported a
series of models predicting different metabolic transformations:
the products of hydroxylation by cytochrome P450 [17], met-
abolic epoxidation centers [18], quinone formation [19], and
metabolic transformation by UDP-glucuronosyltransferase
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